Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective
For patients with lung cancer, toripalimab can considerably extend PFS and OS in the first or second line and in stage III. PD-1 inhibitors are administered to patients with stage IV extensively metastatic lung cancer, which indicates an oligometastatic progression pattern, primarily in 1-3 locations, who are treated with PD-1 inhibitors. Continuing toripalimab beyond disease progression significantly prolonged OS.
Authors
- Jiandong Zhang (ORCID: https://orcid.org/0009-0007-2934-9416)
- Chenlin Wang (ORCID: https://orcid.org/0000-0002-4065-7061)
- Yan Zhang (ORCID: https://orcid.org/0000-0001-7202-9900)
- Yanan Wu (ORCID: https://orcid.org/0000-0002-2268-7558)
- Ning Liang (ORCID: https://orcid.org/0000-0003-0260-2331)
- Lili Qiao
Institutions
- Shandong University (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2024-12-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_500_24
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85